<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Articaine and epinephrine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Articaine and epinephrine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Articaine and epinephrine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8551" href="/d/html/8551.html" rel="external">see "Articaine and epinephrine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11571" href="/d/html/11571.html" rel="external">see "Articaine and epinephrine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F136653"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Articadent;</li>
<li>Orabloc;</li>
<li>Septocaine with Epinephrine 1:100,000;</li>
<li>Septocaine with Epinephrine 1:200,000;</li>
<li>Zorcaine</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52911921"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Astracaine with Epinephrine 1:200,000;</li>
<li>Astracaine with Epinephrine forte 1:100,000;</li>
<li>Karticaine;</li>
<li>Karticaine Forte;</li>
<li>Orabloc 1:100,000;</li>
<li>Orabloc 1:200,000;</li>
<li>Posicaine N;</li>
<li>Posicaine SP;</li>
<li>Septanest N;</li>
<li>Septanest SP;</li>
<li>Ultracaine DS;</li>
<li>Ultracaine DS Forte;</li>
<li>Zorcaine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F999128"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Local Anesthetic</span></li></ul></div>
<div class="block dop drugH1Div" id="F136658"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="477be7c5-8e24-4519-a008-44919f938110">Dental anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dental anesthesia: Note:</b> The provided dosages are guides only; other dosages may be necessary; however, do not exceed maximum recommended dose. The actual volumes to be used depend upon a number of factors, such as type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. In all cases, the smallest dose that will produce the desired result should be used. Two concentrations of epinephrine (1:100,000 or 1:200,00) with 4% articaine are available; when more pronounced hemostasis or improved visualization of the surgical field are required, epinephrine 1:100,000 may be used; in clinical trials of pediatric patients 4 to 16 years of age, the 1:100,000 was also used; in adults, the manufacturer recommends epinephrine 1:200,000 for most routine dental procedures. Dosages should be reduced for patients with cardiac disease and acutely ill and/or debilitated patients. Dosing presented in variable unit (mg/kg, mg, mL/kg, and mL); use extra precaution to verify dosing units.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents ≤16 years: Submucosal infiltration and/or nerve block: Articaine 4%/epinephrine: Injection:</p>
<p style="text-indent:-2em;margin-left:6em;">Simple procedures: Reported range: 0.76 to 5.65 mg/kg of articaine; maximum articaine dose: 7 mg/kg (0.175 mL/kg of 4% solution)</p>
<p style="text-indent:-2em;margin-left:6em;">Complex procedures: 0.37 to 7 mg/kg of articaine; maximum articaine dose: 7 mg/kg (0.175 mL/kg of 4% solution)</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: Submucosal infiltration and/or nerve block: Articaine 4%/epinephrine: Injection:</p>
<p style="text-indent:-2em;margin-left:6em;">Infiltration: 0.5 to 2.5 mL (total articaine dose: 20 to 100 mg); not to exceed 7 mg/kg (0.175 mL/kg of 4% solution) of articaine</p>
<p style="text-indent:-2em;margin-left:6em;">Nerve block: 0.5 to 3.4 mL (total articaine dose: 20 to 136 mg); not to exceed 7 mg/kg (0.175 mL/kg of 4% solution) of articaine</p>
<p style="text-indent:-2em;margin-left:6em;">Oral surgery: 1 to 5.1 mL (total articaine dose: 40 to 204 mg); not to exceed 7 mg/kg (0.175 mL/kg of 4% solution) of articaine</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51065156"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51065157"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Use with caution in patients with severe hepatic disease.</p></div>
<div class="block doa drugH1Div" id="F136654"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8551" href="/d/html/8551.html" rel="external">see "Articaine and epinephrine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="477be7c5-8e24-4519-a008-44919f938110">Dental anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dental anesthesia: </b>Submucosal infiltration and/or nerve block: Articaine 4%/epinephrine: <b>Note:</b> These dosages are guides only; other dosages may be used; however, do not exceed maximum recommended dose. The actual volumes to be used depend upon a number of factors, such as type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. In all cases, the smallest dose that will produce the desired result should be given. For most routine dental procedures, epinephrine 1:200,000 is preferred; when more pronounced hemostasis or improved visualization of the surgical field are required, epinephrine 1:100,000 may be used. Dosages should be reduced for patients with cardiac disease and acutely ill and/or debilitated patients:</p>
<p style="text-indent:-2em;margin-left:4em;">Infiltration: 0.5 to 2.5 mL; total dose of articaine: 20 to 100 mg; maximum dose of articaine: 7 mg/kg (0.175 mL/kg).</p>
<p style="text-indent:-2em;margin-left:4em;">Nerve block: 0.5 to 3.4 mL; total dose of articaine: 20 to 136 mg; maximum dose of articaine: 7 mg/kg (0.175 mL/kg).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral surgery: 1 to 5.1 mL; total dose of articaine: 40 to 204 mg; maximum dose of articaine: 7 mg/kg (0.175 mL/kg).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991447"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988756"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Use with caution in patients with severe hepatic disease.</p></div>
<div class="block adr drugH1Div" id="F136637"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Pain (6% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gingivitis (1%), nausea and vomiting (2%)</p>
<p style="text-indent:-4em;margin-left:6em;">Hypersensitivity: Facial edema (1%)</p>
<p style="text-indent:-4em;margin-left:6em;">Infection: Infection (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (≤1%), headache (3% to 5%), numbness (≤1%), paresthesia (1%), tingling sensation (≤1%), trismus (≤2%)</p>
<p style="text-indent:-4em;margin-left:6em;">Otic: Otalgia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Swelling (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, increased blood pressure, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Ecchymoses, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, dyspepsia, gingival hemorrhage, glossitis, oral mucosa ulcer, sialorrhea, stomatitis, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage, lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Burning sensation at injection site, pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, dizziness, facial nerve paralysis, hyperesthesia, malaise, migraine, nervousness, neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, neck pain, neuromuscular symptoms (exacerbation of Kearns-Sayre syndrome), osteomyelitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Paranasal sinus congestion, pharyngitis, rhinitis, sinus pain</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ischemia</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Tissue necrosis</p></div>
<div class="block coi drugH1Div" id="F136644"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Sulfite hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to articaine, epinephrine, or any component of the formulation; allergies to dental anesthetics; patients with inflammation and/or sepsis near the proposed injection site, severe shock, paroxysmal tachycardia, frequent arrhythmia, neurological disease, severe hypertension; children &lt;4 years of age; anesthesia of fingers, toes, tip of nose, ears, and penis; narrow-angle glaucoma; severe heart disease, heart block, or known arrhythmias; recent (3 to 6 months) myocardial infarction; recent (3 months) coronary artery bypass surgery; concurrent use of non-cardioselective beta-blockers, tricyclic antidepressants, MAO inhibitors, ergot derivatives, and halothane (or other similar inhalation type drugs); pheochromocytoma; thyrotoxicosis; severe hepatic/renal insufficiency; bronchial asthma; intravascular use.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F136634"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Local toxicity: Epinephrine may cause local toxicity, including ischemic injury or necrosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic toxicity: May occur. Systemic absorption of local anesthetics may produce cardiovascular and/or CNS effects. Toxic blood concentrations of local anesthetics depress cardiac conduction and excitability, which may lead to AV block, ventricular arrhythmias, and cardiac arrest (sometimes resulting in death). In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. Restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Small doses of local anesthetics injected into dental blocks may produce adverse reactions similar to systemic toxicity, including confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular stimulation or depression; these reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Constantly monitor cardiovascular and respiratory vital signs and patient's state of consciousness carefully following each injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with impaired cardiovascular function, including patients with heart block. Use local anesthetics containing a vasoconstrictor with caution in patients with vascular disease; patients with peripheral vascular disease or hypertensive vascular disease may exhibit exaggerated vasoconstrictor response, possibly resulting in ischemic injury or necrosis. Dosages should be reduced for patients with cardiac disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic disease (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely-ill/debilitated patients: Administer reduced dosages, commensurate with age and physical condition, to debilitated and/or acutely-ill patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; administer reduced dosages to commensurate with age and physical condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Administer reduced dosages, commensurate with age and physical condition, to pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: May contain sodium metabisulfite, which may cause allergic-type reactions (including anaphylactic symptoms, and life-threatening or less severe asthmatic episodes) in certain susceptible patients. The overall prevalence of the sulfite sensitivity in the general population is unknown, and is seen more frequently in asthmatic than in nonasthmatic persons.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Avoid intravascular injection; accidental intravascular injection may be associated with convulsions, followed by CNS or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: To avoid serious adverse effects and high plasma levels, use the lowest dosage resulting in effective anesthesia. Repeated doses may cause significant increases in blood levels due to the possibility of accumulation of the drug or its metabolites. Dosage recommendations should not be exceeded.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Health care providers should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>
<div class="block foc drugH1Div" id="F136641"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:-2em;margin-left:2em;">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injection, solution [for dental use]:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Articadent:  Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:100,000 (1.7 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Articadent:  Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:200,000 (1.7 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orabloc:  Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:100,000 (1.8 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orabloc:  Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:200,000 (1.8 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Septocaine with epinephrine 1:100,000: Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:100,000 (1.7 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Septocaine with epinephrine 1:200,000: Articaine hydrochloride 4% [40 mg/mL] and epinephrine   1:200,000 (1.7 mL) [contains sodium metabisulfite] </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zorcaine: Articaine hydrochloride 4% [40 mg/mL] and epinephrine 1:100,000 (1.7 mL) [contains sodium metabisulfite]</p></div>
<div class="block geq drugH1Div" id="F136631"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26116605"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (Articadent Dental Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4%-1:100000 (per mL): $0.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (Orabloc Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4%-1:100000 (per mL): $0.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4%-1:200000 (per mL): $0.51</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52911922"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution [for dental use]:</p>
<p style="text-indent:-2em;margin-left:4em;">Astracaine with epinephrine 1:200,000: Articaine hydrochloride 4% and epinephrine 1:200,000 (1.8 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Astracaine Forte with epinephrine forte 1:100,000: Articaine hydrochloride 4% and epinephrine 1:100,000 (1.8 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Septanest N: Articaine hydrochloride 4% and epinephrine 1:200,000 (1.7 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Septanest SP: Articaine hydrochloride 4% and epinephrine 1:100,000 (1.7 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Ultracaine DS: Articaine hydrochloride 4% and epinephrine 1:200,000 (1.7 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;">Ultracaine DS Forte: Articaine hydrochloride 4% and epinephrine 1:100,000 (1.7 mL) [contains sodium metabisulfite]</p></div>
<div class="block admp drugH1Div" id="F52612262"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Dental: For submucosal infiltration and/or nerve block injection. Avoid intravascular injection. Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection.</p></div>
<div class="block adm drugH1Div" id="F48910399"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For submucosal infiltration and/or nerve block injection. Avoid intravascular injection. Aspirate the syringe after tissue penetration and before injection to minimize chance of direct vascular injection.</p></div>
<div class="block sts drugH1Div" id="F48910365"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F) with brief excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Do not freeze.</p></div>
<div class="block usep drugH1Div" id="F53565497"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Local, infiltrative, or conductive anesthesia in both simple and complex dental procedures (FDA approved in ages ≥4 years and adults)</p></div>
<div class="block cyt drugH1Div" id="F13298774"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F136638"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azosemide: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypertensive effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (with Alpha-Blocking Properties): May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bretylium: May enhance the therapeutic effect of Alpha-/Beta-Agonists (Direct-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine.  Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics, but may be administered 20 minutes or more after lidocaine. Avoid all local anesthetics within 96 hours after administration of liposomal bupivacaine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COMT Inhibitors: May increase the serum concentration of COMT Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May diminish the vasoconstricting effect of EPINEPHrine (Systemic). Management: Consider alternatives to this combination and monitor for reduced epinephrine efficacy, and possible paradoxical effects (ie, hypotension), when combined. Use of alternative vasopressor agents (eg, phenylephrine, metaraminol, norepinephrine) is preferred.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Do not use hyaluronidase to enhance the dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic). Management: Administer epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower than normal doses of epinephrine and monitor for the development of cardiac arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: May enhance the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic). Management: Avoid epinephrine and consider norepinephrine or phenylephrine when treating hypotension due to promethazine overdose. Consider alternative vasocontrictors in patients treated with promethazine. This combination may be indicated in anaphylaxis treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Alpha-/Beta-Agonists (Direct-Acting) may enhance the hypertensive effect of Vasopressin. The effect of other hemodynamic parameters may also be enhanced. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F2105784"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies using this combination. Articaine and epinephrine cross the placenta (Sandler 1964; Strasser 1977).</p></div>
<div class="block mopp drugH1Div" id="F53565498"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs, state of consciousness, signs of CNS toxicity (lightheadedness, dizziness, tinnitus, restlessness, tremors, twitching, drowsiness, circumoral paresthesia)</p></div>
<div class="block pha drugH1Div" id="F136633"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Articaine: Blocks both the initiation and conduction of nerve impulses by increasing the threshold for electrical excitation in the nerve, slowing the propagation of the nerve impulse, and reducing the rate of rise of the action potential.</p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine: Increases the duration of action of articaine by causing vasoconstriction (via alpha effects) which slows the vascular absorption of articaine.</p></div>
<div class="block phk drugH1Div" id="F136643"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Also refer to the Epinephrine (Systemic) monograph.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 1 to 9 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Complete anesthesia: ~1 hour (infiltration); ~2 hours (nerve block)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Articaine: ~60% to 80%, bound to albumin and gamma globulins</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Articaine: Hepatic via plasma carboxyesterase to articainic acid (inactive)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Articaine/epinephrine: 43.8 to 44.4 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Articaine: ~25 minutes (single dose); 48 minutes (3 doses)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869365"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Anescart forte | Totalcaina forte</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Orabloc | Septanest mit Epinephrin | Sopira citocartin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Septanest</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ubistesin Adrenaline</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dentocaine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Articaine</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Alphacaine | Septanest adrenalin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Septanest adrenalinee</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Artheek | Septanest con adrenalina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Septanest S Adrenalinem | Ubistesin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Artinestol | Septanest | Sopira citocartin mit epinephrin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dentocaine | Septanest | Septanest 1/100000 | Septanest 1/200000 | Ultracain D-suprarenin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alexadricaine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Artinibsa</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dentocaine | Septocaine | Ubistesin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Predesic adrenaline</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Septanest</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Septanest | Ubistesin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Septanest | Ubistesin | Ubistesin forte</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alfacaina N | Alfacaina sp | Articaina ogna | Artin | Cartidont</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Primacaine adrenaline</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Posicaine | Septanest</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Citocartin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dentocaine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dentocaine | Septanest | Ubistesin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Artinibsa | Primacaine adrenaline | Septanest adrenalinee</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Medicaine | Turbocaina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Posicaine | Primacaine adrenaline | Ubistesin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Septanest | Ultracain d-s</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Septocaine | Septocaine forte</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ardanest | Ubistesin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Citocartin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Articadent dental | Orabloc | Septocaine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Artinibsa</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Septanest con adrenalina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Artinibsa with Epinephrine | Orabloc | Septanest</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ubistesin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alphacaine sp | Articain | Articain df | Articain+adrenalin | Articaine df | Articaine Inibsa | Articaine+epinephrine | Artifrin | Artifrin forte | Artikain s adrenalinom | Brilocaine adrenaline | Citocartin | Orabloc | Primacaine adrenaline | Septanest with adrenaline | Ubistesin | Ubistesin forte | Ultracain d-s</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Septocaine | Septocaine forte | Ubistesin | Ubistesin forte</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Septanestepi | Ubistesin | Ultracain d-s</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Orabloc | Septanest</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Septanest | Septanest sp | Ubistesin | Ubistesin forte</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Orabloc | Posicaine | Septanest with adrenaline | Ubistesin | Ubistesin forte</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Artifrin | Brilocaine adrenaline | Orabloc | Ultracain d-s</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Carticaina forte epicaris</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Septanest with adrenaline | Ubistesin | Ubistesin forte</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Articadent (articaine and epinephrine) [prescribing information]. York, PA: Dentsply Pharmaceutical; December 2020.</div>
</li>
<li>
<div class="reference">
                  Astracaine dental with epinephrine (articaine and epinephrine) [product monograph]. Woodbridge, Ontario, Canada: Dentsply Canada; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19840499">
<a name="19840499"></a>Gaffen AS and Haas DA, "Retrospective Review of Voluntary Reports of Nonsurgical Paresthesia in Dentistry," <i>J Can Dent Assoc</i>, 2009, 75(8):579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/articaine-and-epinephrine-pediatric-drug-information/abstract-text/19840499/pubmed" id="19840499" target="_blank">19840499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20592403">
<a name="20592403"></a>Garisto GA, Gaffen AS, Lawrence HP, et al, "Occurrence of Paresthesia After Dental Local Anesthetic Administration in the United States," <i>J Am Dent Assoc</i>, 2010, 141(7):836-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/articaine-and-epinephrine-pediatric-drug-information/abstract-text/20592403/pubmed" id="20592403" target="_blank">20592403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17082283">
<a name="17082283"></a>Hersh EV, Giannakopoulos H, Levin LM, et al, “The Pharmacokinetics and Cardiovascular Effects of High-Dose Articaine With 1:100,000 and 1:200,000 Epinephrine,” <i>J Am Dent Assoc</i>, 2006, 137(11):1562-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/articaine-and-epinephrine-pediatric-drug-information/abstract-text/17082283/pubmed" id="17082283" target="_blank">17082283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10969438">
<a name="10969438"></a>Malamed SF, Gagnon S, Leblanc D, “A Comparison Between Articaine HCl and Lidocaine HCl in Pediatric Dental Patients,” <i>Pediatr Dent</i>, 2000, 22(4):307-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/articaine-and-epinephrine-pediatric-drug-information/abstract-text/10969438/pubmed" id="10969438" target="_blank">10969438</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Malamed SF, Gagnon S, Leblanc D, “Articaine Hydrochloride: A Study of the Safety of a New Amide Local Anesthetic,” <i>J Am Dent Assoc</i>, 2001, 132(2):177-85.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17082284">
<a name="17082284"></a>Moore PA, Boynes SG, Hersh EV, et al, “The Anesthetic Efficacy of 4 Percent Articaine 1:200,000 Epinephrine: Two Controlled Clinical Trials,” <i>J Am Dent Assoc</i>, 2006, 137(11):1572-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/articaine-and-epinephrine-pediatric-drug-information/abstract-text/17082284/pubmed" id="17082284" target="_blank">17082284</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Orabloc (articaine and epinephrine) [prescribing information]. Capua, Italy: Pierrel Pharma; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Orabloc.1">
<a name="Orabloc.1"></a>Orabloc (articaine and epinephrine) [product monograph]. Oakville, Ontario, Canada: Innomar Strategies Inc; February 2023.</div>
</li>
<li>
<div class="reference">
                  Sandler M, Ruthren CR, Wood C. Metabolism of C14-norepinephrine and 14-epinephrine and their transmission across the human placenta. <i>Int J Neuropharmacol</i>. 1964;3:123-128. doi:10.1016/0028-3908(64)90055-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/articaine-and-epinephrine-pediatric-drug-information/abstract-text/14334587/pubmed" id="14334587" target="_blank">14334587</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Septocaine (articaine and epinephrine) [prescribing information]. Lancaster, PA: Septodont; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-878538">
<a name="878538"></a>Strasser K, Huch A, Huch R, Uihein M. Placental transfer of carticaine (Ultracain) a new local anesthetic agent (author's transl). <i>Z Geburtshilfe Perinatol</i>. 1977;181(2):118-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/articaine-and-epinephrine-pediatric-drug-information/abstract-text/878538/pubmed" id="878538" target="_blank">878538</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM Clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med.</i> 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/articaine-and-epinephrine-pediatric-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15055644">
<a name="15055644"></a>Wynn RL, Bergman SA, and Meiller TF, “Paresthesia Associated With Local Anesthetics: A Perspective on Articaine,” <i>Gen Dent</i>, 2003, 51(6):498-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/articaine-and-epinephrine-pediatric-drug-information/abstract-text/15055644/pubmed" id="15055644" target="_blank">15055644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zorcaine.1">
<a name="Zorcaine.1"></a>Zorcaine (articaine and epinephrine) [prescribing information]. Cambridge, Ontario, Canada: Novocol Pharmaceutical of Canada Inc; February 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 118184 Version 78.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
